Back to Alzheimers Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02063308

NCT02063308
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with mild or moderate Alzheimer's disease
  • You have a study partner (such as a family member or caregiver) who can participate alongside you
  • English is your first or main language

Who may not be able to join:

  • You do not have a study partner available to take part with you
  • You have a serious medical condition that could interfere with the study, such as type 1 diabetes, cancer, or a recent heart-related event (such as a heart attack or angioplasty)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Russell Swerdlow, MD
Registry
clinicaltrials_gov
Start date
1 February 2014
Est. completion
1 June 2014

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Correlation between oral OAA intake and plasma levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov